stella
beta
Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLC — Stella
Recruiting
Back to SCLC trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(2 sites)
China
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing
Xinqiao Hospital, Third Military Medical University, Chongqing
View full record on ClinicalTrials.gov